ATLANTA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Snap Inc. (“Snap” or the “Company”) (NYSE: SNAP). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding the true state of Snap’s advertising revenue growth rate. If you purchased shares of Snap between April 29, 2025, and August 5, 2025, and experienced a significant loss on that investment, you are encouraged t ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for allegedly making false statements and engaging in deceptive practices related to the promotion and sale of Wegovy®, leading to a significant drop in stock price after the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, to seek lead plaintiff status [1][4]. - The lawsuit alleges that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [2][3]. - Following the announcement of the partnership termination by Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Company Background - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects during the pandemic period [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of all individuals and entities who purchased Petco securities between January 14, 2021, and June 5, 2025 [1]. - Investors have until August 29, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Petco - The lawsuit claims that Petco's pandemic-related business advantages were unsustainable and that its business model focused on premium pet food was flawed [3]. - It is alleged that the strength of Petco's differentiated product strategy was overstated, and the company downplayed the severity of the issues it faced [3]. - The defendants are accused of overstating Petco's ability to achieve sustainable and profitable growth, which has negatively impacted its comparable sales metrics [3].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making materially false and misleading statements regarding its business operations and growth prospects during the pandemic [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of all individuals and entities who purchased Petco securities between January 14, 2021, and June 5, 2025 [1]. - Investors have until August 29, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Petco - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [3]. - It is alleged that the company downplayed the severity of operational issues and the necessary changes to address them, which could negatively impact comparable sales metrics [3]. - The defendants are accused of overstating Petco's ability to achieve sustainable and profitable growth [3].

Core Points - A shareholder class action lawsuit has been filed against CTO Realty Growth, Inc. alleging that the company's dividends were less sustainable than previously communicated to investors [1] - The lawsuit claims that CTO Realty used deceptive practices to artificially inflate its Adjusted Funds from Operations and overstate the profitability of its Ashford Lane property [1] - The lawsuit suggests that CTO Realty's business and financial prospects were overstated as a result of these practices [1] Legal Information - Shareholders who purchased CTO Realty shares between February 18, 2021, and June 24, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is October 7, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of shareholders who purchased securities between August 10, 2023, and June 25, 2025, alleging that the company misrepresented the results of its IMPACT Phase 2b MASH trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that Altimmune created a false impression regarding the reliability of information related to the IMPACT Phase 2b MASH trial results, specifically failing to meet a key statistical significance marker for fibrosis reduction [4]. - Altimmune allegedly inflated expectations for positive results while concealing adverse data from the placebo group, which negatively impacted the topline results [4]. - When the true results were disclosed, investors reportedly suffered damages due to the misleading information provided by Altimmune [4]. Group 2: Participation Information - Shareholders who purchased Altimmune securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][5]. - A lead plaintiff must file a motion with the court by October 6, 2025, to represent other class members in the litigation [1][3].

Core Points - A shareholder class action lawsuit has been filed against Vestis Corporation, alleging that the company made materially false and misleading statements regarding its business growth potential [1] - The lawsuit specifically targets shareholders who purchased shares between May 2, 2024, and May 6, 2025, and experienced significant losses [2] - The deadline for shareholders to apply to be appointed as lead plaintiff in the case is August 8, 2025 [3] Legal Representation - Holzer & Holzer, LLC is representing the shareholders in this litigation, known for its strong track record in securities litigation [3] - The firm has recovered hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Core Points - A shareholder class action lawsuit has been filed against Replimune Group, Inc. alleging that the company made materially false and misleading statements regarding the IGNYTE trial's prospects [1] - The lawsuit claims that the defendants overstated the trial's prospects despite known material issues, leading the FDA to deem the trial inadequate and not well-controlled [1] - As a result of these actions, the statements made by the defendants about Replimune's business, operations, and prospects were considered materially false and misleading [1] Legal Information - Shareholders who purchased Replimune shares between November 22, 2024, and July 21, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is September 22, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects during the pandemic [3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Petco securities between January 14, 2021, and June 5, 2025, with a deadline of August 29, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its product strategy and ability to achieve sustainable growth [3]. Group 2: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors in this class action lawsuit and encourages affected parties to contact them for more information [4][5].

Group 1 - A shareholder class action lawsuit has been filed against Alto Neuroscience, Inc. alleging that the company made materially false and/or misleading statements regarding its business and operations [1] - The lawsuit claims that ALTO-100 was less effective in treating Major Depressive Disorder (MDD) than previously communicated to investors, leading to overstated clinical, regulatory, and commercial prospects [1] - As a result of these allegations, the lawsuit asserts that Alto's overall business and financial prospects were also overstated [1] Group 2 - Investors who purchased shares of Alto between February 2, 2024, and October 22, 2024, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for investors to request to be appointed as lead plaintiff in the case is September 19, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in representing shareholders and has a history of recovering significant amounts for investors affected by corporate misconduct [3]